ES8802616A1 - Un procedimiento para preparar una formulacion farmaceutica que contiene 3'-azido-3'-desoxitimidina o uno de sus derivados farmaceuticamente aceptables. - Google Patents

Un procedimiento para preparar una formulacion farmaceutica que contiene 3'-azido-3'-desoxitimidina o uno de sus derivados farmaceuticamente aceptables.

Info

Publication number
ES8802616A1
ES8802616A1 ES557836A ES557836A ES8802616A1 ES 8802616 A1 ES8802616 A1 ES 8802616A1 ES 557836 A ES557836 A ES 557836A ES 557836 A ES557836 A ES 557836A ES 8802616 A1 ES8802616 A1 ES 8802616A1
Authority
ES
Spain
Prior art keywords
treatment
htlv
viral infections
deoxythymidine
azido
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES557836A
Other languages
English (en)
Other versions
ES557836A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellcome Foundation Ltd
Original Assignee
Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26288986&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES8802616(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB858506869A external-priority patent/GB8506869D0/en
Priority claimed from GB858511774A external-priority patent/GB8511774D0/en
Application filed by Wellcome Foundation Ltd filed Critical Wellcome Foundation Ltd
Publication of ES557836A0 publication Critical patent/ES557836A0/es
Publication of ES8802616A1 publication Critical patent/ES8802616A1/es
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/15—Suppositories

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

LA 3''-ACIDO-3''-DESOXITIMIDINA SE OBTIENE HACIENDO REACCIONAR UN COMPUESTO (II), DONDE R1 ES HIDROXILO PROTEGIDO O NO, CON UN COMPUESTO (II), DONDE R1 ES HIDROXILO PROTEGIDO O NO, CON UN COMPUESTO ACIDO EN UN DISOLVENTE ORGANICO ENTRE LA TEMPERATURA AMBIENTE Y LA DE REFLUJO. APLICABLE AL TRATAMIENTO DE INFECCIONES RETROVIRICAS HUMANAS Y EN PARTICULAR EL VIRUS III CAUSANTE DEL SIDA EN ASOCIACION CON ACICLOVIR O INTERFERON. *FORMULA*
ES557836A 1985-03-16 1988-04-29 Un procedimiento para preparar una formulacion farmaceutica que contiene 3'-azido-3'-desoxitimidina o uno de sus derivados farmaceuticamente aceptables. Expired ES8802616A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB858506869A GB8506869D0 (en) 1985-03-16 1985-03-16 Antiviral compound
GB858511774A GB8511774D0 (en) 1985-05-09 1985-05-09 Antiviral compounds

Publications (2)

Publication Number Publication Date
ES557836A0 ES557836A0 (es) 1988-09-01
ES8802616A1 true ES8802616A1 (es) 1988-09-01

Family

ID=26288986

Family Applications (2)

Application Number Title Priority Date Filing Date
ES557835A Expired ES8802615A1 (es) 1985-03-16 1988-04-29 Un procedimiento para preparar una formulacion farmaceutica que contiene 3'-azido-3'-desoxitimidina o uno de sus derivados farmaceuticamente aceptables.
ES557836A Expired ES8802616A1 (es) 1985-03-16 1988-04-29 Un procedimiento para preparar una formulacion farmaceutica que contiene 3'-azido-3'-desoxitimidina o uno de sus derivados farmaceuticamente aceptables.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES557835A Expired ES8802615A1 (es) 1985-03-16 1988-04-29 Un procedimiento para preparar una formulacion farmaceutica que contiene 3'-azido-3'-desoxitimidina o uno de sus derivados farmaceuticamente aceptables.

Country Status (2)

Country Link
US (9) US4724232A (es)
ES (2) ES8802615A1 (es)

Families Citing this family (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4724232A (en) * 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
US5093114A (en) * 1985-03-16 1992-03-03 Burroughs Wellcome Co. Treatment of human viral infections
US5683990A (en) * 1985-03-16 1997-11-04 Glaxo Wellcome Inc. Treatment of human viral infections
US4795744A (en) * 1986-07-17 1989-01-03 Hem Research, Inc. Modulation of AIDS virus-related events by double-stranded RNAS
DK167377B1 (da) * 1985-09-17 1993-10-25 Wellcome Found 3'-azidopyrimidinnucleosider eller farmaceutisk acceptable salte eller estere deraf til anvendelse ved behandling af eller profylakse for en human retrovirusinfektion
US5077279A (en) * 1986-05-01 1991-12-31 University Of Georgia Research Foundation, Inc. 3'-azido-2',3'-dideoxy-5-methylcytidine anti-viral composition
US4841039A (en) * 1986-05-01 1989-06-20 Emory University 2',3'-dideoxy-5-substituted uridines and related compounds as antiviral agents
US5084445A (en) * 1986-05-01 1992-01-28 University Of Georgia Research Foundation, Inc. 3'-azido-2',3'-dideoxy-5-methylcytidine
US4916122A (en) * 1987-01-28 1990-04-10 University Of Georgia Research Foundation, Inc. 3'-Azido-2',3'-dideoxyuridine anti-retroviral composition
US5086044A (en) * 1986-06-23 1992-02-04 Burroughs Wellcome Co. Treatment of human viral infections
US5446029A (en) * 1986-07-04 1995-08-29 Medivir Ab Anti-retroviral activity of 2',3'-dideoxy-3'-fluoronucleosides
SE8602981D0 (sv) 1986-07-04 1986-07-04 Astra Laekemedel Ab Novel medicinal use
US4880782A (en) * 1986-11-21 1989-11-14 Max-Planck-Gesellschaft Zur Foederung Der Wissenschaften E.V. Method of treating viral infections in humans and compositions therefor
US5190926A (en) * 1987-01-28 1993-03-02 University Of Georgia Research Foundation, Inc. 3'-azido-2',3'-dideoxypyrimidines and related compounds as antiviral agents
EP0286825A3 (en) * 1987-03-18 1989-04-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Use of 3'-fluro-3' deoxythymidine for the manufacture of a medicament for the treatment of virus infections
US4950652A (en) * 1987-03-23 1990-08-21 Hem Research, Inc. dsRNAs for combination therapy in the treatment of viral diseases
GB8707421D0 (en) * 1987-03-27 1987-04-29 Wellcome Found Pharmaceutical formulations
US5187163A (en) * 1987-03-27 1993-02-16 Baker Norton Pharmaceuticals, Inc. Anti-viral compounds, dosage forms and methods
IL86007A0 (en) * 1987-04-09 1988-09-30 Wellcome Found 6-substituted purine nucleosides,their preparation and pharmaceutical compositions containing them
US5185437A (en) * 1987-04-09 1993-02-09 Burroughs Wellcome Co. Therapeutic nucleosides
SE8701605D0 (sv) * 1987-04-16 1987-04-16 Astra Ab Novel medicinal compounds
NL194728C (nl) * 1987-04-16 2003-01-07 Hollis Eden Pharmaceuticals Farmaceutisch preparaat geschikt voor de profylaxe of therapie van een retrovirale infectie of een complicatie of gevolg daarvan.
US4837311A (en) * 1987-06-22 1989-06-06 Hoffman-La Roche Inc. Anti-retroviral compounds
USRE33887E (en) * 1987-06-22 1992-04-14 Hoffmann-La Roche Inc. Anti-retroviral compounds
US4900548A (en) * 1987-11-13 1990-02-13 Harvard University Use of diethylcarbamazine to enhance antigen-antibody and antigen-host immune cell interactions
WO1989005152A1 (en) * 1987-12-09 1989-06-15 The Regents Of The University Of California Liposome-encapsulated anti-viral composition and method
US5631370A (en) * 1988-01-20 1997-05-20 Regents Of The University Of Minnesota Optically-active isomers of dideoxycarbocyclic nucleosides
US5175292A (en) * 1988-01-20 1992-12-29 Regents Of The University Of Minnesota Intermediates for the preparation of dideoxycarbocyclic nucleosides
US5025800A (en) * 1988-01-26 1991-06-25 Zelson Steve T Contraceptive device
WO1989009056A1 (en) * 1988-03-23 1989-10-05 New York University Antiviral composition containing aromatic polycyclic diones and nucleoside analogs and method for treating retrovirus infections
AU3294289A (en) * 1988-03-23 1989-10-16 New York University Antiviral composition containing aromatic polycyclic diones and nucleoside analogs and method for treating retrovirus infections
CA1329119C (en) * 1988-03-29 1994-05-03 Milton David Goldenberg Cytotoxic therapy
US20030232010A2 (en) * 1988-03-29 2003-12-18 Immunomedics, Inc. Improved cytotoxic therapy
US5120525A (en) * 1988-03-29 1992-06-09 Immunomedics, Inc. Radiolabeled antibody cytotoxic therapy of cancer
US5077280A (en) * 1988-04-12 1991-12-31 Brown University Research Foundation Treatment of viral infections
US5122517A (en) * 1988-06-10 1992-06-16 Regents Of The University Of Minnesota Antiviral combination comprising nucleoside analogs
WO1989011860A1 (en) * 1988-06-10 1989-12-14 Biogen, Inc. Combinations of soluble t4 proteins and anti-retroviral agents and methods for treating or preventing aids, arc and hiv infection
US5051361A (en) * 1988-10-19 1991-09-24 Sigma Chemical Company AZT immunoassays, derivatives, conjugates and antibodies
US5132291A (en) * 1989-01-24 1992-07-21 Gensia Pharmaceuticals, Inc. Antivirals and methods for increasing the antiviral activity of azt
IL93682A (en) * 1989-03-16 1996-06-18 Yeda Res & Dev Polycyclic compounds with antigypical activity are used in the manufacture of medicines and pharmaceutical preparations containing them
US5686428A (en) * 1989-04-07 1997-11-11 Aktiebolaget Astra Pharmaceutical composition
JP2831030B2 (ja) * 1989-05-12 1998-12-02 学校法人城西大学 ３’‐アジド‐３’デオキシチミジンを有効成分とする経皮投与製剤用組成物
US5011829A (en) * 1989-06-02 1991-04-30 G. D. Searle & Co. Pharmaceutical composition and method of inhibiting virus
SE464168B (sv) * 1989-07-19 1991-03-18 Bo Fredrik Oeberg Antiviral komposition bestaaende av en 3'-fluoro-2',3'-dideoxynukleosidfoerening och en 2',3'-dideoxynukleosidfoerening (exempelvis azt)
KR910007655A (ko) * 1989-10-03 1991-05-30 엠. 피. 잭슨 치료용 뉴클레오시드
US5563142A (en) * 1989-12-28 1996-10-08 The Upjohn Company Diaromatic substituted compounds as anti-HIV-1 agents
US5580577A (en) * 1990-01-11 1996-12-03 Herzenberg; Leonard A. Method of treating the symptoms of human rhinovirus infection
US5116823A (en) 1990-02-27 1992-05-26 Roger Williams General Hospital Drug combinations containing AZT
WO1991013623A1 (en) * 1990-03-09 1991-09-19 Memorial Hospital For Cancer And Allied Diseases C-5 mono-substituted barbiturates in combination with therapeutic agents and uses thereof
US5137724A (en) * 1990-05-23 1992-08-11 Stichting Rega Vzw Combinations of TS-inhibitors and viral TK-inhibitors in antiherpetic medicines
SE9003151D0 (sv) * 1990-10-02 1990-10-02 Medivir Ab Nucleoside derivatives
US5276143A (en) * 1990-12-21 1994-01-04 E. I. Du Pont De Nemours And Company Dideoxyfructonucleosides and deoxyfructonucleotides
GB9104740D0 (en) * 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
US6812233B1 (en) * 1991-03-06 2004-11-02 Emory University Therapeutic nucleosides
US5220003A (en) * 1991-03-29 1993-06-15 The Regents Of The University Of California Process for the synthesis of 2',3'-dideoxynucleosides
US5221669A (en) * 1991-04-19 1993-06-22 The United States Of America As Represented By The Department Of Health And Human Services Antiviral compositions containing α-cyclodextrin sulfates alone and in combination with other known antiviral agents and glucocorticoids and methods of treating viral infections
US5633235A (en) * 1991-04-19 1997-05-27 Regents Of The University Of Michigan Triciribine and analogs as antiviral drugs
US5234914A (en) * 1991-06-11 1993-08-10 Patent Biopharmaceutics, Inc. Methods of treating hemorrhoids and anorecial disease
HUT63852A (en) * 1991-06-21 1993-10-28 Acic Canada Inc Process for producing antiviral compounds and pharmaceutical compositions comprising same as active ingredient
US5599930A (en) * 1991-07-03 1997-02-04 The Upjohn Company Substituted indoles as anti-AIDS pharmaceuticals
IL102548A (en) * 1991-08-02 1998-08-16 Medivir Ab Use of painting derivatives in the preparation of drugs for VIH inhibition and treatment of SDIA and new compounds
US5231174A (en) * 1992-02-27 1993-07-27 University Of Iowa Research Foundation 2'isodideoxy-β-D-nucleosides as stable antiviral agents
US5700461A (en) * 1992-08-19 1997-12-23 Schering Corporation Method for inhibiting HIV replication using IL-4
US5723490A (en) * 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
GB9226927D0 (en) * 1992-12-24 1993-02-17 Iaf Biochem Int Dideoxy nucleoside analogues
AU5960894A (en) * 1992-12-29 1994-07-19 Rolland Chen Treatment of viral infections
US5512671A (en) * 1993-02-16 1996-04-30 Wake Forest University Ether lipid-nucleoside covalent conjugates
EP0631783A1 (en) * 1993-06-03 1995-01-04 Mitsubishi Chemical Corporation Antiviral combinations of 2',3'-di-deoxyribonucleosides with 6-benzyl-1-ethoxymethyl-5-substituted uracil derivatives
US5576355A (en) * 1993-06-04 1996-11-19 Mobil Oil Corp. Diamondoid derivatives for pharmaceutical use
US20020120130A1 (en) * 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
CA2171550C (en) 1993-09-10 2008-08-26 Raymond F. Schinazi Nucleosides with anti-hepatitis b virus activity
NZ276286A (en) * 1993-11-12 2001-06-29 Upjohn Co Substituted pyrimidine thio- or oxy-alkyl derivatives and medicaments
US5466787A (en) * 1993-11-15 1995-11-14 Bristol-Myers Squibb Company Process for preparing AZT
IT1272252B (it) * 1994-05-16 1997-06-16 Applied Research Systems Formulazioni liquide di interferone beta
EP1852121A3 (en) 1994-08-29 2007-11-21 Wake Forest University Lipid analogs for treating viral infections
US7135584B2 (en) * 1995-08-07 2006-11-14 Wake Forest University Lipid analogs for treating viral infections
US6689761B1 (en) * 1995-02-01 2004-02-10 Merck & Co., Inc. Combination therapy for HIV infection
US6576622B1 (en) * 1995-03-14 2003-06-10 University Of Medicine & Dentistry Of New Jersey Drug combination for the treatment of viral diseases
MY115461A (en) * 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc
UA56992C2 (uk) * 1995-05-08 2003-06-16 Фармація Енд Апджон Компані <font face="Symbol">a</font>-ПІРИМІДИНТІОАЛКІЛЗАМІЩЕНІ ТА <font face="Symbol">a</font>-ПІРИМІДИНОКСОАЛКІЛЗАМІЩЕНІ СПОЛУКИ
US5939286A (en) * 1995-05-10 1999-08-17 University Of Florida Hybrid interferon tau/alpha polypeptides, their recombinant production, and methods using them
ES2276404T3 (es) * 1995-06-07 2007-06-16 Emory University Nucleosidos con actividad antivirus de la hepatitis-b.
US5840711A (en) * 1995-06-21 1998-11-24 University Of Kentucky Research Foundation Compositions containing lithium inorganic salts and anti-viral drugs and method of treating viral infections such as acquired immunodeficiency syndrome
EP0852499B1 (en) * 1995-09-07 2010-03-03 University Of Georgia Research Foundation, Inc. Therapeutic azide compounds
CA2189097A1 (en) 1995-11-15 1997-05-16 Pin-Fang Lin Composition and method of treating retroviral infection
US5869493A (en) 1996-02-16 1999-02-09 Medivir Ab Acyclic nucleoside derivatives
US6204022B1 (en) 1996-04-12 2001-03-20 Pepgen Corporation And University Of Florida Low-toxicity human interferon-alpha analogs
PL330791A1 (en) * 1996-06-25 1999-06-07 Glaxo Group Ltd Vx478, zidovudin, ftc and/or 3tc containing combinations for use in treating hiv infections
ID19490A (id) 1996-06-25 1998-07-16 Glaxo Group Ltd Kombinasi-kombinasi antiviral
US5719132A (en) * 1996-06-27 1998-02-17 Bristol-Myers Squibb Company Compositions and methods of treating HIV with d4T, 5-fluorouracil/tegafur, and uracil
DE19632823C1 (de) * 1996-08-14 1997-11-20 Symbio Herborn Group Gmbh & Co Komplexe zwischen S-(+)-Adenosylmethionin und 3'-Azido-2',3'-didesoxynucleosid als potente Inhibitoren der HIV-Replikation
US7067117B1 (en) 1997-09-11 2006-06-27 Cambridge University Technical Services, Ltd. Compounds and methods to inhibit or augment an inflammatory response
US6989435B2 (en) 1997-09-11 2006-01-24 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
WO1999019304A2 (en) * 1997-09-25 1999-04-22 Pharmacia & Upjohn Company Alpha-alkylthio substituted pyrimidine ethers and thioethers as viral reverse transcriptase inhibitors
US6040434A (en) * 1997-12-01 2000-03-21 Inaba; Tadanobu Aldehyde oxidase inhibitors for treatment of aids
US6136814A (en) * 1997-12-08 2000-10-24 Fujisawa Usa, Inc. Aqueous acyclovir product
EP1047432A1 (en) * 1997-12-24 2000-11-02 Visible Genetics Inc. Drug-directed mutagenesis/drug-driven selection for lethal mutants
WO1999048371A1 (en) * 1998-03-27 1999-09-30 The Regents Of The University Of California Novel hiv integrase inhibitors and hiv therapy based on drug combinations including integrase inhibitors
US6309632B1 (en) 1998-04-28 2001-10-30 Immunex Corporation Methods for treating HIV-infected patients by administering GM-CSF
CA2343522A1 (en) * 1998-09-04 2000-03-16 Viropharma Incorporated Methods for treating or preventing viral infections and associated diseases
WO2000016625A1 (en) * 1998-09-23 2000-03-30 University Of Kentucky Research Foundation Antiviral drug compositions containing lithium inorganic salts
EP1124418A4 (en) * 1998-11-06 2004-05-26 Schering Ag USE OF GM-CSF TO INHIBIT MEDICINE RESISTANCE DEVELOPMENT IN HIV-POSITIVE PATIENTS
US7238711B1 (en) 1999-03-17 2007-07-03 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
US6511983B1 (en) * 1999-03-01 2003-01-28 Biochem Pharma Inc. Pharmaceutical combination of antiviral agents
US6849605B1 (en) * 1999-03-05 2005-02-01 The Trustees Of University Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of viral infections
US7205404B1 (en) * 1999-03-05 2007-04-17 Metabasis Therapeutics, Inc. Phosphorus-containing prodrugs
US6107303A (en) * 1999-03-15 2000-08-22 Demarco; Charlene C. Treatment of Epstein Barr infection
US7186736B1 (en) * 1999-03-20 2007-03-06 Parker Hughes Institute NNI for treatment of multi-drug resistant HIV
US6225307B1 (en) * 1999-03-31 2001-05-01 The Procter & Gamble Company Viral treatment
US6653318B1 (en) * 1999-07-21 2003-11-25 Yale University 5-(E)-Bromovinyl uracil analogues and related pyrimidine nucleosides as anti-viral agents and methods of use
US7026469B2 (en) * 2000-10-19 2006-04-11 Wake Forest University School Of Medicine Compositions and methods of double-targeting virus infections and cancer cells
IT1318424B1 (it) * 2000-03-24 2003-08-25 Unihart Corp Composti con attivita' anti-hiv.
KR20030019423A (ko) * 2000-06-13 2003-03-06 시오노기세이야쿠가부시키가이샤 프로페논 유도체를 함유하는 의약 조성물
US7012086B1 (en) * 2000-06-30 2006-03-14 The Foundation For Innovative Therapies, Inc. Treatment of retrovirus induced derangements with niacin compounds
GB0016845D0 (en) * 2000-07-07 2000-08-30 Leuven K U Res & Dev Pharmaceutical composition for treatment of HIV infection
US7309696B2 (en) 2000-10-19 2007-12-18 Wake Forest University Compositions and methods for targeting cancer cells
US20020107193A1 (en) * 2000-11-09 2002-08-08 Glazner Gordon W. Therapeutic uses for IP3 receptor-mediated calcium channel modulators
US20050049242A1 (en) * 2000-12-21 2005-03-03 W. Edward Robinson Novel HIV integrase inhibitors and HIV therapy based on drug combinations including integrase inhibitors
WO2002096826A2 (en) * 2001-05-29 2002-12-05 Koninklijke Philips Electronics N.V. Metal-ceramic bond
CN1568369A (zh) * 2001-08-12 2005-01-19 派普根公司 杂合的干扰素/干扰素Tau蛋白、组合物和使用方法
JP4714413B2 (ja) * 2001-08-31 2011-06-29 トムソン ライセンシング オーディオビジュアルストリームのためのシーケンスカウンタ
JP4625637B2 (ja) 2002-02-22 2011-02-02 シャイア エルエルシー 活性物質送達系及び活性物質を保護し投与する方法
RU2293739C2 (ru) * 2002-07-26 2007-02-20 Закрытое акционерное общество "Производственно-коммерческая Ассоциация АЗТ" 5`-холинфосфат 3`-азидо-3`-дезокситимидина как антивирусный агент
CA2505130C (en) * 2002-11-08 2009-10-06 Glaxo Group Limited Pharmaceutical compositions
US20040182427A1 (en) * 2003-03-19 2004-09-23 Goettl John M. Method and apparatus for channeling debris in a swimming pool
WO2005023270A2 (en) * 2003-09-09 2005-03-17 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Compositions and methods for use of antiviral drugs in the treatment of retroviral diseases resistant to nucleoside reverse transcriptase inhibitors
US20050187191A1 (en) * 2004-02-20 2005-08-25 Kucera Louis S. Methods and compositions for the treatment of respiratory syncytial virus
EP1778251B1 (en) 2004-07-27 2011-04-13 Gilead Sciences, Inc. Nucleoside phosphonate conjugates as anti hiv agents
LV13544B (en) 2005-08-15 2007-05-20 Grindeks As Pharmaceutical composition containing reverse transcriptase inhibitor and meldonium
DE102006037786A1 (de) * 2006-08-11 2008-03-20 Resprotect Gmbh Nukleoside, diese enthaltendes Arzneimittel und deren Verwendung
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
WO2010049438A2 (en) * 2008-10-30 2010-05-06 Innate Pharma Improved methods of using phosphoantigens for the treatment of diseases
ES2623794T3 (es) 2008-12-09 2017-07-12 Gilead Sciences, Inc. Intermedios para la preparación de moduladores de receptores tipo toll
MX2011006891A (es) * 2008-12-23 2011-10-06 Pharmasset Inc Fosforamidatos de nucleosidos.
NZ593647A (en) 2008-12-23 2013-08-30 Gilead Pharmasset Llc Synthesis of purine nucleosides
EP2376514A2 (en) * 2008-12-23 2011-10-19 Pharmasset, Inc. Nucleoside analogs
US9226970B2 (en) 2010-02-22 2016-01-05 Nektar Therapeutics Oligomer modified diaromatic substituted compounds
US20110223131A1 (en) 2010-02-24 2011-09-15 Gilead Sciences, Inc. Antiviral compounds
AU2011235112B2 (en) 2010-03-31 2015-07-09 Gilead Pharmasset Llc Nucleoside phosphoramidates
US8518409B2 (en) 2010-05-31 2013-08-27 Imperium Biotechnologies, Inc. System for selective cell treatment using ideotypically modulated pharmacoeffectors
US8383405B2 (en) 2010-05-31 2013-02-26 Imperium Biotechnologies, Inc. Methods of using ideotypically modulated pharmacoeffectors for selective cell treatment
AU2013340559B2 (en) 2012-10-29 2018-03-15 Cipla Limited Antiviral phosphonate analogues and process for preparation thereof
US10449210B2 (en) 2014-02-13 2019-10-22 Ligand Pharmaceuticals Inc. Prodrug compounds and their uses
WO2016001907A1 (en) 2014-07-02 2016-01-07 Prendergast Patrick T Mogroside iv and mogroside v as agonist/stimulator/un-blocking agent for toll-like receptor 4 and adjuvant for use in human/animal vaccine and to stimulate immunity against disease agents.
CN106687118A (zh) 2014-07-02 2017-05-17 配体药物公司 前药化合物及其用途
PL3166607T3 (pl) 2014-07-11 2023-02-20 Gilead Sciences, Inc. Modulatory receptorów toll-podobnych do leczenia hiv
MA42818A (fr) 2015-09-15 2018-07-25 Gilead Sciences Inc Modulateurs de récepteurs de type toll pour le traitement du vih
EP3515447A4 (en) * 2016-09-26 2020-05-27 Tufts University NUCLEOSIDE URIDINE DERIVATIVES, COMPOSITIONS AND METHODS OF USE
AU2019207625A1 (en) 2018-01-09 2020-07-30 Ligand Pharmaceuticals, Inc. Acetal compounds and therapeutic uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1963998A1 (de) * 1968-12-24 1970-11-12 Takeda Chemical Industries Ltd Interferon induzierendes Mittel,Verfahren zu seiner Herstellung und Verfahren zur Interferon-Induktion durch Verwendung dieses Mittels
GB1523865A (en) * 1974-09-02 1978-09-06 Wellcome Found Purine compunds and salts thereof
US4230698A (en) * 1978-05-12 1980-10-28 Research Corporation 2-Substituted arabinofuranosyl nucleosides and nucleotides
US4649140A (en) * 1982-10-14 1987-03-10 Burroughs Wellcome Co. Purine derivatives
US4695570A (en) * 1982-10-14 1987-09-22 Burroughs Wellcome Co. Antiviral compound use
SE8406538D0 (sv) * 1984-12-21 1984-12-21 Astra Laekemedel Ab Novel derivatives of purine
US4724232A (en) * 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
US4723232A (en) * 1987-01-27 1988-02-02 Beebe William B Pendulum indicator horological device
US5521161A (en) * 1993-12-20 1996-05-28 Compagnie De Developpment Aguettant S.A. Method of treating HIV in humans by administration of ddI and hydroxycarbamide

Also Published As

Publication number Publication date
US4828838A (en) 1989-05-09
US4724232A (en) 1988-02-09
ES8802615A1 (es) 1988-09-01
US4818538A (en) 1989-04-04
US4874609A (en) 1989-10-17
US5885957A (en) 1999-03-23
ES557835A0 (es) 1988-09-01
US4837208A (en) 1989-06-06
US5643891A (en) 1997-07-01
US4833130A (en) 1989-05-23
ES557836A0 (es) 1988-09-01
US4780453A (en) 1988-10-25

Similar Documents

Publication Publication Date Title
ES8802615A1 (es) Un procedimiento para preparar una formulacion farmaceutica que contiene 3&#39;-azido-3&#39;-desoxitimidina o uno de sus derivados farmaceuticamente aceptables.
DE69535047D1 (de) L-Nukleoside zur Behandlung des Hepatitis-B- und Epstein-Bar-Virus
ES2115918T3 (es) Nucleosidos de beta-d-dioxolano de pureza enantiomera y de actividad dirigida selectivamente contra el virus de la hepatitis b.
IL87257A0 (en) Purification of hepatitis a virions
ES8705764A1 (es) Procedimiento fotodinamico de inactivacion de virus
ATE135365T1 (de) Antivirale verbindungen
SE8602981D0 (sv) Novel medicinal use
DE69823984D1 (de) Synthese und anti-hiv und anti-hepatitis virus aktivität von 1,3-oxaselenolan nucleosiden
DK615788A (da) Nucleosidforbindelser til anvendelse mod virale infektioner
ATE78692T1 (de) Antivirale therapie gegen hepatitis b mit 2&#39;,3&#39;- didesoxynucleosiden.
DK462688A (da) Anvendelse af nukleosider til fremstilling af laegemiddel til behandling af sygdomme foraarsaget af retrovirus eller hepatitis b virus
ES2105923A1 (es) Composiciones para el tratamiento de una infeccion y una enfermedad causadas por el virus de la hepatitis b (hbv).
DE69324244T2 (de) Therapeutische nukleoside der 2&#39;,3&#39;-dideoxy-3&#39;-fluor -purin reihe
ES546974A0 (es) Un procedimiento de eliminacion del virus lav.
ES2014042A6 (es) Un procedimiento para la preparacion de una composicion de 1-(2&#39;-desoxi -2&#39; fluor -b- d- arabinofuranosil) -5-etiluracilo.
ATE232108T1 (de) Interleukin - 8 als antivirale- und antitumorwirkstoffe
ATE26267T1 (de) Pyrimidin-derivate, ausgestattet mit antiviraler wirkung.
TR200102388T2 (tr) Kronik viral enfeksiyonların m. vaccae ile tedavisi.
JPS6471815A (en) Antiviral composition containing 5-amino-2- (4-methylpiperidine-1-yl)phenyl-4- chlorophenylmethanone
TW217986B (en) Compositions for the treatment of infection and disease caused by HBV
IL90783A0 (en) Antiviral method for human immuno deficiency virus
TH10132A (th) การยับยั้งไวรัสที่ทำให้เกิดภูมิคุ้มกันบกพร่องในคน (hiv) โดยการทำงานร่วมกันแบบเสริมของอนุพันธุ์นิวคลีโอไซด์
MY101495A (en) Treatment of diseases caused by viruses
BR8404558A (pt) Tratamento de doencas causadas pelos virus do herpes